


IN THE CLAIMS:

1. (Cancelled)


2. (Currently amended) The ~~pharmaceutical agent according to Claim 1, method of claim 5 wherein the pharmaceutical agent comprises~~ a compound of formula (Ia):



~~in which the groups R¹ to R² have the meaning specified in Claim 1, and wherein~~ R⁹ is an alkyl group having 1-4 C atoms which, optionally, are substituted ~~or replaced~~ by with halogen or replaced by halogen;

~~or of a pharmaceutically acceptable salt of such a compound thereof.~~


3. (Currently amended) The ~~pharmaceutical agent according to Claim 1, comprising the method of claim 5 wherein the pharmaceutical agent comprises a~~ compound of formula (III):



or of a pharmaceutically acceptable salt of such a compound thereof.

4. (Cancelled)

5. (Currently amended) A ~~chemotherapeutic~~ method for a chemotherapeutic treatment of neuropathies characterized by application to a patient of a pharmaceutical agent comprising a compound of formula (I):



(I)

in which

R¹=C₁₋₆alkyl, optionally substituted with halogen,

R²=hydrogen or C₁₋₄alkyl, optionally substituted with halogen or replaced with halogen,

R³=C₂₋₄alkyl, optionally substituted with halogen,

R⁴=SO₂NR⁵R⁶,

C₁₋₄alkyl, optionally substituted with NR⁵R⁶, CN, CONR⁵R⁶, CO₂R⁷, or halogen,

C₂₋₄alkenyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

C₂₋₄alkanoyl, optionally substituted with NR⁵R⁶, SONR⁵R⁶, CONR⁵R⁶, CO₂R⁷, or halogen,

R⁵ and R⁶, independent of one another, represent hydrogen or C₁₋₄alkyl, or, together with the nitrogen atom to which they are attached, represent a pyrrolidino, piperidino, morpholino, 4-(NR⁸)-1-pipera-

zinyll or 1-imidazolyl ring which, optionally, may be substituted with one or two C₁₋₄alkyl groups,

R⁷=hydrogen or C₁₋₄alkyl, optionally, substituted with fluorine, and

R⁸=hydrogen, C₁₋₃alkyl, or hydroxy alkyl having 1-4 C atoms, or ~~of~~ a pharmaceutically acceptable salt ~~of such a compound~~ thereof.

6. (Previously presented) The method of claim 5, wherein from 1-100 mg/day of said pharmaceutical agent is administered to a patient being treated.

7. (Previously presented) The method of claim 5, wherein from 5-50 mg/day of said pharmaceutical agent is administered to a patient being treated.

8. (Previously presented) The method of claim 5, wherein from 25-50 mg/day of said pharmaceutical agent is administered to a patient being treated.

9. (New) The method of claim 5 wherein the neuropathy comprises a peripheral diabetic polyneuropathy.

10. (New) The method of claim 5 wherein the neuropathy comprises gastroparesis.